A Pivotal Bioequivalence Study of DOXIL/CAELYX Manufactured at a New Site in Subjects With Advanced or Refractory Solid Malignancies Including Subjects With Ovarian Cancer.

Trial Profile

A Pivotal Bioequivalence Study of DOXIL/CAELYX Manufactured at a New Site in Subjects With Advanced or Refractory Solid Malignancies Including Subjects With Ovarian Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2015

At a glance

  • Drugs Doxorubicin (Primary)
  • Indications Advanced breast cancer; Ovarian cancer; Solid tumours
  • Focus Pharmacokinetics; Registrational
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 26 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 30 Jul 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Feb 2016 to 1 May 2015.
    • 01 May 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top